Leap Together
Leap Together
Podcast Description
This is the Leap Together podcast, where we highlight top leaders driving breakthroughs in clinical research and life sciences.
Podcast Insights
Content Themes
The podcast focuses on themes related to clinical research, patient engagement, and healthcare equity. Specific topics include barriers to clinical trial participation, the role of technology in research, and the importance of patient advocacy, with episodes such as making clinical trials more accessible featuring leaders like Zachary Gobst who share their expertise and personal stories.

This is the Leap Together podcast, where we highlight top leaders driving breakthroughs in clinical research and life sciences.
In this epsiode of Leap Together, Tris Pharma’s Head of Clinical Operations, Liza Micioni, distills 25+ years of end-to-end study leadership. She discusses how durable physician relationships speed decisions and drive site follow-through, and how steady cross-functional rhythms keep “your delay becomes my delay” from taking root.
Liza unpacks the real trade-offs of the clin-ops triangle: time, budget, and quality. She explains that quality is non-negotiable, while timelines and budgets need to flex to meet reality. She shares practical stories of creative, “figure-it-out” logistics, when extending a timeline is the right call, and a grounded take on where AI truly helps (and where it doesn’t) in today’s trials.
Above all, her north star never wavers: improving individual lives, one patient at a time.

Disclaimer
This podcast’s information is provided for general reference and was obtained from publicly accessible sources. The Podcast Collaborative neither produces nor verifies the content, accuracy, or suitability of this podcast. Views and opinions belong solely to the podcast creators and guests.
For a complete disclaimer, please see our Full Disclaimer on the archive page. The Podcast Collaborative bears no responsibility for the podcast’s themes, language, or overall content. Listener discretion is advised. Read our Terms of Use and Privacy Policy for more details.